ARTICLE | Clinical News
Nadroparin cardiovascular data
December 15, 2008 8:00 AM UTC
In the double-blind PROTECHT study in 1,166 cancer patients, once-daily subcutaneous nadroparin met the primary endpoint of significantly fewer thromboembolic events vs. placebo (2.1% vs. 3.9%, p=0.03...